Skip to content
MarketScale
‹ Back to IndustriesHealthcare

A New Startup Promises to Preserve Your Brain Intact

If your end-of-life goals include preserving your brain completely intact at the synaptic level so it can potentially be reproduced in microdetail in the distant future and your consciousness reborn, then you’re in luck! A company called Nectome, with financial support from the U.S. National Institute of Mental Health and the startup accelerator Y Combinator,…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

If your end-of-life goals include preserving your brain completely intact at the synaptic level so it can potentially be reproduced in microdetail in the distant future and your consciousness reborn, then you’re in luck! A company called Nectome, with financial support from the U.S. National Institute of Mental Health and the startup accelerator Y Combinator, plans to provide you this opportunity.

Nectome has perfectly preserved a pig brain—and amazingly, the brain of a recently deceased woman—using their technique. However, because the process requires the brain’s owner to be alive, the woman’s brain sustained some damage. Their success with the pig brain creates hope for a special population—terminally ill humans who wish to be euthanized using this technique.

Unfortunately, the procedure is literally a suicide mission, which of course raises ethical and legal concerns. Euthanasia is a crime in many states. However, with the end goal being life reproduced, the federal financing targets the development of the process, revitalizing brain research.

Those who undergo the future revival procedure should not expect their consciousness to emerge in the future as themselves. The brain dies in this process, experiencing a combination of cryogenics and embalming. If successful, an identical consciousness with all your precious memories, knowledge, and wisdom would be would be created. That’s a lot to wrap your head around.

Scientists hypothesize that consciousness is a product of the architecture of the neural network instead of some other aspect of the brain, such as its biochemical composition or nucleic acid sequences. Right now, we do not know enough to guarantee specific outcomes. This research would undoubtedly answer many questions. However, as with countless other biomedical experiments, there may be no definitive answers to ethical questions surrounding the wisdom and intentions of manipulating life in this manner. Regardless of these issues, the technique will likely yield promising, much-needed neurological research. And we will be one step closer to solving the mysteries of the human brain.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512